University of California San Francisco
Give to UCSF
Over 30 UCSF Scientists Honored for Highest Impact in Their Fields
Thirty-two UCSF scientists are among the most influential individuals in their respective fields, according to the most recent analysis of research citations by the science and intellectual property company, Clarivate.
From the First Bite, Our Sense of Taste Helps Pace Our Eating
A previously unknown signaling cycle stemming from our sense of taste helps suppress our appetites.
Does a Headache Have to Be the Price for Drinking Red Wine?
Researchers offer a theory for why many people experience headaches as soon as 30 minutes after drinking red wine.
Can Gene Expression Predict if a Brain Tumor Is Likely to Grow Back?
A gene expression test can accurately predict the best treatment for meningioma patients by measuring the aggressiveness of their tumors and adjusting treatment accordingly.
Why Progress in Alzheimer’s Disease Treatment Has Taken 30 Years
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
Neuroscientists to Reveal New Insights into Alzheimer's
UCSF experts to discuss amyloid therapies and dementia research at CTAD conference, addressing equity, novel treatments, and innovative studies.
Could the Neurons That Make You Scratch Be the Solution for Itch?
Scientists found that the nervous system tamps down allergic response, which could change how asthma, Crohn’s and other inflammatory diseases are treated.
$151M Grant Will Drive New Era in Alzheimer’s Treatments
A new study will combine an Alzheimer’s medication that slows disease progression in some patients with two other drugs to see if their effects can be amplified.
Will a Pill Help New Moms Bounce Back from Postpartum Depression?
Zuranolone (Zurzuvae), the first pill for patients suffering from postpartum depression, is expected to be available by the end of 2023. Though it may relieve depressive symptoms, it has some drawbacks such as sedation and dangers in breastfeeding.
MDMA’s Latest Trial Results Offer Hope for Patients with PTSD
A clinical trial showed that MDMA, the so-called psychedelic drug also known as "ecstasy" or "molly," can be a powerful new tool in treating people with moderate-to-severe PTSD.
